colorectal+cancer结直肠癌最新研究发展（英文版）.pdfVIP

Seminar Colorectal cancer David Cunningham, Wendy Atkin, Heinz-Josef Lenz, Henry T Lynch, Bruce Minsky, Bernard Nordlinger, Naureen Starling Lancet 2010; 375: 1030–47 Substantial progress has been made in colorectal cancer in the past decade. Screening, used to identify individuals Gastrointestinal Unit, Royal at an early stage, has improved outcome. There is greater understanding of the genetic basis of inherited colorectal Marsden Hospital National cancer and identifi cation of patients at risk. Optimisation of surgery for patients with localised disease has had a Health Service Foundation major eff ect on survival at 5 years and 10 years. For rectal cancer, identification of patients at greatest risk of local Trust, London and Surrey, UK (Prof D Cunningham MD, failure is important in the selection of patients for preoperative chemoradiation, a strategy proven to improve N Starling MRCP); Department outcomes in these patients. Stringent postoperative follow-up helps the early identifi cation of potentially radically of Surgery and Cancer, Imperial treatable oligometastatic disease and improves long-term survival. Treatment with adjuvant fl uoropyrimidine for College, London, UK colon and rectal cancers further improves survival, more so in stage III than in stage II disease, and oxaliplatin- (Prof W Atkin PhD); Sharon Carpenter Laboratory, based combination chemotherapy is now routinely used for stage III disease, although efficacy must be carefully University of Southern balanced against toxicity. In stage II disease, molecular markers such as microsatellite instability might help California/Norris select patients for treatment. The integration of targeted treatments with conventional cytotoxic